Navigation Links
EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
Date:9/10/2007

n preclinical development for rheumatoid arthritis, and ENMD-2076, a dual-acting Aurora-angiogenesis inhibitor, is in preclinical development for cancer. EntreMed's goal is to develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell-cycle regulation and inflammation -- processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company's web site at http://www.entremed.com and in various filings with the Securities and Exchange Commission.

Forward Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance (including the timing of royalty revenues and future R&D expenditures), strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in Securities and Exchange Commission filings under "Risk Factors," including risks relating to the need for additional capital and the uncertainty of additional funding; variations in actual sales of Thalomid(R), risks associated with the Company's product candidates; the early-stage products under development; results in preclinical models are not necessarily indicative of clinical results, uncertainties relating to preclinical and clinical trials; success in the clinical development of any products; dependence on third parties; future capital needs; and risks relating to the commercialization, if any, of the Company's proposed products (such a
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Clinical Results From EntreMeds Panzem NCD and Taxol Breast Cancer Study Presented at ASCO
2. Phase 2 Results for EntreMeds Panzem NCD Brain Cancer Study Presented at ASCO
3. EntreMeds Aurora Kinase Inhibitor Induces Tumor Regression in Preclinical Models
4. EntreMed Presents Preclinical Data for MKC-1 in Hematological Cancers
5. EntreMed Presents Multi-Mechanism Results for ENMD-1198 at AACR Annual Meeting
6. EntreMed Presents Multi-Mechanism Antitumor Data for ENMD-1420 in Preclinical Models
7. EntreMed Presents Mechanism Data for Its Three Lead Oncology Compounds
8. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
9. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
10. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
11. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... /PRNewswire-iReach/ -- ScriptPro has been certified by the ... Security Framework (CSF). According to Russ Hailey ... appreciate this rigorous, top-to-bottom audit. Security-minded customers depend ... signifies. Our business partners need to know we ... PROCESS: ScriptPro,s internal security processes and controls were ...
(Date:8/21/2014)... Aug. 21, 2014  ACI Clinical ( www.aciclinical.com ... Data Monitoring Committees. Using this solution, ... over industry standard costs and receive the same ... in committee services. Leveraging a decade ... contracting, charter development, statistical programming and meeting facilitation), ...
(Date:8/21/2014)... SAN FRANCISCO , Aug. 21, 2014 ... U.S. Food and Drug Administration (FDA) has ... to detect atrial fibrillation (AFib), the most ... analysis process (algorithm) instantly detects if patients ... recordings taken on the mobile phone based ...
Breaking Medicine Technology:ScriptPro Achieves HITRUST Certification 2ACI Clinical: Innovation and Savings in Data Safety Monitoring Committees 2AliveCor Receives First FDA Clearance to Detect a Serious Heart Condition in an ECG on a Mobile Device 2
... Industry-Funded Immune Globulin Study Uncovers Sample,Manipulation, Design ... -- An analysis,released today critically examined a ... autism and Rh immune globulin,(RhIg) injections, some ... extensive design flaws, the,analysis uncovered manipulation of ...
... OSS, the Netherlands, June 27, 2007-Organon, the human,healthcare ... two,out of three Phase III clinical trials with ... have reached,their randomization target. , ,Corifollitropin alfa ... first of a new class of gonadotropins (a ...
Cached Medicine Technology:Genetics Journal Thimerosal/Autism Study the 'Best Science Drug,Company Money Can Buy' 2Genetics Journal Thimerosal/Autism Study the 'Best Science Drug,Company Money Can Buy' 3Two Phase III clinical trials on corifollitropin alfa (Org 36286),reach randomization target 2Two Phase III clinical trials on corifollitropin alfa (Org 36286),reach randomization target 3
(Date:8/21/2014)... THURSDAY, Aug. 21, 2014 (HealthDay News) -- Black mothers ... babies, and here,s one possible reason why: Hospitals in ... nursing than those in areas with more white residents, ... support breast-feeding are much less common in medical centers ... from the U.S. Centers for Disease Control and Prevention ...
(Date:8/21/2014)... born at a low birth weight puts black women at ... The findings may partly explain high diabetes rates among ... low birth weight, the researchers added. Their study of ... low birth weight were 13 percent more likely to develop ... The risk of diabetes was 40 percent higher in those ...
(Date:8/21/2014)... Dennis Thompson HealthDay Reporter ... A combination of therapy and antidepressants appears to best ... study reports. Four out of five people suffering ... full recovery when treated with cognitive therapy plus antidepressant ... combination didn,t work much better than drugs alone in ...
(Date:8/21/2014)... August 21, 2014 Transvaginal mesh ... Inc. continue to move forward in the federal ... District of West Virginia, Bernstein Liebhard LLP reports. ... 14th, the Court has established new stipulated evidence ... handling, division, storage and preservation. (In re C.R. ...
(Date:8/21/2014)... 21, 2014 Seattle, WA chiropractors ... Eastlake Chiropractic and Massage Center have recently ... team. Rina Lang, LMP and Mike Larios, LMP ... of massage techniques, and have developed their expertise working ... is particularly important in a clinical environment where massage ...
Breaking Medicine News(10 mins):Health News:Racial Disparities in Breast-Feeding May Start With Hospitals, Study Suggests 2Health News:Low Birth Weights May Put Black Women at Risk for Diabetes 2Health News:Talk Therapy Plus Meds May Be Best for Severe Depression 2Health News:Talk Therapy Plus Meds May Be Best for Severe Depression 3Health News:Transvaginal Mesh Lawsuits Move Forward in Federal C.R. Bard Litigation with Issuance of New Pretrial Order, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuits Move Forward in Federal C.R. Bard Litigation with Issuance of New Pretrial Order, Bernstein Liebhard LLP Reports 3Health News:Seattle’s Eastlake Chiropractic and Massage Center Is Pleased to Introduce Rina Lang and Mike Larios as New Members of Its Massage Therapy Team 2Health News:Seattle’s Eastlake Chiropractic and Massage Center Is Pleased to Introduce Rina Lang and Mike Larios as New Members of Its Massage Therapy Team 3
... are used in some men to help them improve ... characteristics. Apparently the same patches can be used in ... their sexual desire and activity. ,In a study ... have looked at 447 women diagnosed with hypoactive sexual ...
... want to know answers to everything. This gains special// importance ... often have we questioned the diseases that make our precious ... ,Researchers in a breakthrough have unraveled the mystery surrounding heart ... failure, the heart uses too much fatty acid and not ...
... disease is responsible for nearly half (49 per cent) ... million people each year. Reducing cholesterol is one of ... ,Both soy protein and plant sterols extracted from ... foods market, with the US Food and Drug Administration ...
... D in bone development and teeth// strengthening is well known. Children ... the body with this vital nutrient. Vitamin D is produced in ... exposed to sunlight too. So much so that parents want their ... vitamin, which is free in nature! All this is done to ...
... tomographic colonography (CTC) depicts cancers and other clinically important conditions ... at very little additional cost, according to a study in ... finding cancer outside the colon may be as significant as ... Yee, M.D., Chief of Radiology at the Veterans Affairs Medical ...
... causes that can cause hearing loss in people apart// ... and type 1 diabetes. The researches are featured in ... ,In the first study researchers have found a previously ... form of hearing loss due to a lesion of ...
Cached Medicine News:Health News:Testosterone Patches Found To Increase Sexual Desire In Menopausal Women 2Health News:Calcium-Vitamin D Combo For Reduced Fracture Risk 2Health News:Calcium-Vitamin D Combo For Reduced Fracture Risk 3Health News:Virtual Colonoscopy May Be Better Than Real-time Colonoscopy 2Health News:Studies On Hearing Loss Discovers New Causes 2
The P45 Ultrasonic Workstation provides the highest ultrasound resolution for imaging....
EchoScan US-2500 is available in a single configuration or in combination with the A scan for maximum cost efficiency....
PremierEdge Stab Knives - 30....
... in the 21st century requires ... Alcon® UltraScan® imaging system responds ... at clinical echographic needs in ... permits step-by-step processing to collect ...
Medicine Products: